Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Analyst downgrades Salesforce to a sell rating due to slowing growth in key segments and AI posing a risk to revenue model.

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Lockheed Martin’s fourth-quarter earnings per share topped expectations, while the top line disappointed. The outlook was mixed, as well.

When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...

Highlights:,Merck & Co., (NYSE:MRK),, Inc. shares opened at nearly $98 on Tuesday.,The company has a market capitalization of ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $97.94 which represents a slight increase of $2.39 or 2.50% from the prior close of $95.55. The stock opened at $96.63 and touched a ...

Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Merck & Company (MRK – Research Report). The ...

Merck & Co. Inc. closed 27.25% short of its 52-week high of $134.63, which the company reached on June 25th.